Abstract:ABSTRACT The rational design of HIV-1 immunogens to trigger the development of broadly neutralizing antibodies (bNAbs) requires understanding the viral evolutionary pathways influencing this process. An acute HIV-1-infected individual exhibiting >50% plasma neutralization breadth developed neutralizing antibody specificities against the CD4-binding site (CD4bs) and V1V2 regions of Env gp120. Comparison of pseudoviruses derived from early and late autologous env sequences demonstrated the development of >2 log resistance to VRC13 but not to other CD4bs-specific bNAbs. Mapping studies indicated that the V3 and CD4-binding loops of Env gp120 contributed significantly to developing resistance to the autologous neutralizing response and that the CD4-binding loop (CD4BL) specifically was responsible for the developing resistance to VRC13. Tracking viral evolution during the development of this cross-neutralizing CD4bs response identified amino acid substitutions arising at only 4 of 11 known VRC13 contact sites (K282, T283, K421, and V471). However, each of these mutations was external to the V3 and CD4BL regions conferring resistance to VRC13 and was transient in nature. Rather, complete resistance to VRC13 was achieved through the cooperative expression of a cluster of single amino acid changes within and immediately adjacent to the CD4BL, including a T359I substitution, exchange of a potential N -linked glycosylation (PNLG) site to residue S362 from N363, and a P369L substitution. Collectively, our data characterize complex HIV-1 env evolution in an individual developing resistance to a VRC13-like neutralizing antibody response and identify novel VRC13-associated escape mutations that may be important to inducing VRC13-like bNAbs for lineage-based immunogens. IMPORTANCE The pursuit of eliciting broadly neutralizing antibodies (bNAbs) through vaccination and their use as therapeutics remains a significant focus in the effort to eradicate HIV-1. Key to our understanding of this approach is a more extensive understanding of bNAb contact sites and susceptible escape mutations in HIV-1 envelope ( env ). We identified a broad neutralizer exhibiting VRC13-like responses, a non-germline restricted class of CD4-binding site antibody distinct from the well-studied VRC01-class. Through longitudinal envelope sequencing and Env-pseudotyped neutralization assays, we characterized a complex escape pathway requiring the cooperative evolution of four amino acid changes to confer complete resistance to VRC13. This suggests that VRC13-class bNAbs may be refractory to rapid escape and attractive for therapeutic applications. Furthermore, the identification of longitudinal viral changes concomitant with the development of neutralization breadth may help identify the viral intermediates needed for the maturation of VRC13-like responses and the design of lineage-based immunogens.

Aberrant B cell repertoire selection associated with HIV neutralizing antibody breadth

B cell repertoire sequencing of HIV-1 pediatric elite-neutralizers identifies multiple broadly neutralizing antibody clonotypes

A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope

Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses

Immune Perturbations in HIV-1–infected Individuals Who Make Broadly Neutralizing Antibodies

Preservation of memory B cell homeostasis in an individual producing broadly neutralising antibodies against HIV-1

Parallel HIV-1 fitness landscapes shape viral dynamics in humans and macaques that develop broadly neutralizing antibodies.

Neutralization activity in chronic HIV infection is characterized by a distinct programming of follicular helper CD4 T cells

Autoreactivity and Broad Neutralization of Antibodies Against HIV-1 Are Governed by Distinct Mutations: Implications for Vaccine Design Strategies

The Potential Of The Human Immune System To Develop Broadly Neutralizing Hiv-1 Antibodies: Implications For Vaccine Development

Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals

Development of Neutralization Breadth against Diverse HIV‐1 by Increasing Ab–Ag Interface on V2

Short CDRL1 in intermediate VRC01-like mAbs is not sufficient to overcome key glycan barriers on HIV-1 Env

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

Tracing HIV-1 strains that imprint broadly neutralizing antibody responses

Augmenting Neutralization Breadth Against Diverse HIV-1 by Increasing the Ab-Ag Interface on V2

Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies

Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates

Contemporary HIV-1 consensus Env with AI-assisted redesigned hypervariable loops promote antibody binding

Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth